Cancer Drug May Help Scleroderma Oct 22, 2009
The drug is approved in the United States to treat two types of cancer -- chronic myeloid leukemia and gastrointestinal stromal tumor. SOURCE: Hospital for Special Surgery, news release, Oct. 17, 2009. (MEDLINEplus)
Drug could provide first treatment for scleroderma Oct 18, 2009
Gleevec is approved in the United States for two types of cancer: chronic myeloid leukemia and gastrointestinal stromal tumor. Systemic scleroderma affects not only the skin, but also underlying blood vessels, and often muscles and joints, as well as the gastrointestinal tract, kidneys, lungs and heart. (EurekAlert!)
Crystal Ball For Brain Cancer? New Method Predicts Which Brain Tumors Will Respond To Drug Aug 9, 2009
29, 2009) Researchers have uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor patients respond to the targeted therapy imatinib mesylate. Moreover, their findings point to. (Science Daily)
Racial Disparities for One Type of Tumor Disappear Aug 4, 2009
Using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry, Dr. Leonidas G. Koniaris and colleagues from the University of Miami, Florida, compared outcomes of patients diagnosed gastrointestinal stromal tumors (GIST) before and after imatinib was introduced in 2000. According to their report in the Journal of the American College of Surgeons, 3795 patients were diagnosed with GIST between 1992 and 2005, with 30 percent diagnosed before 2000. (MEDLINEplus)
Gene signature may predict patient response to therapy for gastrointestinal stromal tumors May 15, 2009
Public release date: 14-May-2009. Contact: Diana Quattrone. (EurekAlert!)
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery May 8, 2009
Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)- update of NCCN clinical practice guidelines ... Choi et al, Response evaluation of Gastrointestinal Stromal Tumors ... Corless, CL et al. Biology of Gastrointestinal Stromal Tumors. (PR Newswire)
Predicting Patient Response To Gleevec In Gastrointestinal Stromal Tumors Apr 29, 2009
(May 15, 2008) Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors could indicate that the patient would be less responsive to Gleevec. Preliminary studies have shown that. (Science Daily)
Novartis posts 14 percent drop in 1Q profit Apr 28, 2009
The drug is targeted for certain forms of chronic myeloid leukemia and gastrointestinal stromal tumors. Related Searches. (Yahoo News -- Pharmaceutical Industry News)
Infinity to Present Preclinical Data From Its Hsp90 Inhibitor Program and Its Hedgehog Signaling Pathway Inhibitor Program At AACR Meeting Apr 8, 2009
21, 2009: 1:00 - 5:00 p.m. MDT Poster Session Title: Efficacy of IPI-504 "a novel inhibitor of heat shock protein 90" in a preclinical mouse model of gastrointestinal stromal tumor (GIST) Presenter: Giuseppe Floris, Catholic University of Leuven, Belgium Location: Hall B-F, Poster Section 37 Tuesday, Apr. 21, 2009: 1:00 - 5:00 p.m. MDT Poster Session Title: The antiproliferative activity of IPI-504 does not depend on the cellular oxidoreductase NQ01 Presenter: Emmanuel Normant, Infinity... (Primezone Releases)
Lancet data signal urgent need for patient access to life-saving cancer treatment Apr 1, 2009
GUELPH, ON, April 1 /CNW/ - Clinical study results just published in the journal The Lancet confirm Gleevec (imatinib mesylate) as a safe and effective post-surgical treatment for patients with gastrointestinal stromal tumors (GIST), and signal the urgent need for patient access to this life-saving treatment. In fact, this Phase III clinical trial was halted early, after investigators found that 98 per cent of patients with primary GIST, who had received Gleevec for one year following surgery,... (Canada Newswire)
Infinity Initiates International Phase 2 Trial of IPI-504 in Combination With Herceptin(r) in Patients With HER2-Positive Breast Cancer Mar 30, 2009
Infinity is evaluating the potential of Hsp90 inhibition in a broad range of cancers, The RING trial is an international Phase 3 registration trial in patients with refractory gastrointestinal stromal tumors that positions IPI-504 as the potential first-in-class Hsp90 inhibitor. IPI-504 is also being evaluated in a Phase 2 study in patients with advanced non-small cell lung cancer and in a Phase 1b combination study with Taxotere(r) (docetaxel) in patients with advanced solid tumors. (Primezone Releases)
Gleevec Prevents Return of Intestinal Cancer, Study Confirms Mar 21, 2009
THURSDAY, March 19 (HealthDay News) -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed. Gastrointestinal stromal tumors (GIST), the most common soft-tissue cancer of the intestinal tract, typically occur in the stomach or small intestine ... Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and his fellow researchers said that their "findings will affect the management of patients with primary... (MEDLINEplus)
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports Mar 19, 2009
EAST HANOVER, N.J., March 18, 2009 /PRNewswire/ -- Data published today online and in an upcoming print issue of The Lancet show that Gleevec(R) (imatinib mesylate) tablets*, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo ... About gastrointestinal stromal tumors (GIST) ... Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas(3). (PR Newswire)
Pfizer Rises After Cancer Drug Succeeds in Trial Mar 13, 2009
Sutent is already marketed for renal cell carcinoma and as a secondary treatment for gastrointestinal stromal tumors. Pfizer stopped the trial after getting a positive recommendation from an independent committee. (ABC News -- Wire)
